Patent Fight Bounces Bristol-Myers CEO

Peter Dolan's missteps in trying to secure an anticlotting drug's profitability led to his dismissal from the drugmaker's top post

The test of a drug company isn't just how good it is at developing new medicines, it's also how well its executives fight the patent wars.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.